Search results
Nov 8, 2023 · November 8, 2023. Download PDF. Adults taking Zepbound in a clinical trial lost on average 48 lb. at the highest dose. Zepbound is the first and only approved treatment activating two incretin hormone receptors, GIP and GLP-1, to tackle an underlying cause of excess weight.
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy. The drug is called...
Oct 15, 2023 · Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks | Eli Lilly and Company. News Release.
Zepbound is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. Zepbound should be used with a reduced-calorie diet and increased physical activity.
Nov 8, 2023 · Blood sugar drug tirzepatide also leads to substantial weight loss in diabetes patients, Eli Lilly says. The drug, called Mounjaro for diabetes, will be called Zepbound for weight...
Apr 28, 2022 · INDIANAPOLIS, April 28, 2022 /PRNewswire/ -- Tirzepatide (5 mg, 10 mg, 15 mg) achieved superior weight loss compared to placebo at 72 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURMOUNT-1 clinical trial, with participants losing up to 22.5% (52 lb. or 24 kg) of their body weight for the efficacy estimand i.
Nov 8, 2023 · Today, the U.S. Food and Drug Administration approved Zepbound (tirzepatide) injection for chronic weight management in adults with obesity (body mass index of 30 kilograms per square meter...
